The first targeted multiple entities of critical importance in PC pathobiology, such as AR (with its V7 variant), the Mnk1/2 pathway or the epithelial-mesenchymal transition, while the latter appeared to target the cancer stem cell population. This evidence concerns the gene AR and pachyonychia congenita.